MedPath

Intra-arterial injection of donor mesenchymal stromal cells for treating refractory acute Graft-vs-Host disease after hemopoietic stem cell transplantatio

Phase 1
Conditions
refractory acute GVHD
Registration Number
JPRN-UMIN000000845
Lead Sponsor
Department of Hematology, The Tazuke Kofukai Medical Research Institute Kitano Hospital
Brief Summary

Enrolled case:3 Bone marrow collection & MSC culture:3 Culture using with FCS:0 MSC administration:3(intra-arterial) Early side effects:0 CR:0 PR:1 NC:1 PD:1

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
8
Inclusion Criteria

Not provided

Exclusion Criteria

1.Positive for HIV Ab 2.Uncontrollable infection such as mucor, EBV-LPD, Gancyclovir-refractory CMV, measles. 3.severe psychiatric disorder

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical response at 2 weeks after MSC therapy
Secondary Outcome Measures
NameTimeMethod
Clinical response at 4 weeks after MSC therapy Overall survival at 4 weeks after MSC therapy
© Copyright 2025. All Rights Reserved by MedPath